New treatment guidelines for migraine headache are in development under the auspices of the American Headache Society. The basis of these is contained in a paper appearing in this month’s issue of the AHS journal Headache assessing the efficacy of current migraine therapies. The authors noted that the current treatment guidelines published in 2000 by the AHS and the American Academy of Neurology (AAN) predate the completion of several large randomized pharmacological trials, and that a review and update is therefore in order.
The authors further note that their report focuses on the treatment of acute migraine attacks, and that “Clinicians still need to individualize treatment and consider the clinical context of the migraine attack.” Drug classes found to meet “Level A” criteria in the study (established as effective for treating acute migraine) included triptans, dihydroergotamine (DHE), many NSAIDs, butorphanol nasal spray, and the combination medications sumatriptan/naproxen and acetaminophen/aspirin/caffeine. Several other medications were considered “probably effective” or “possibly effective.”
To read about potential migraine surgery for adolescents, click here:
Read a news story about the recommendations, with link to the study, here.